story of the week
Venetoclax Plus Tamoxifen in ER− and BCL-2+ Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Cancer Discovery
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Phase 1b Dose-Escalation and Expansion Study of the BCL-2 Inhibitor Venetoclax Combined With Tamoxifen in ER and BCL-2-Positive Metastatic Breast Cancer
Cancer Discov 2018 Dec 05;[EPub Ahead of Print], GJ Lindeman, SW Lok, JR Whittle, F Vaillant, CE Teh, LL Lo, AN Policheni, ART Bergin, J Desai, S Ftouni, LC Gandolfo, D Liew, HK Liu, GB Mann, K Moodie, A Murugasu, B Pal, AW Roberts, MA Rosenthal, K Shackleton, MJ Silva, ZR Siow, GK Smyth, L Taylor, A Travers, B Yeo, MM Yeung, A Zivanovic Bujak, SJ Dawson, DHD Gray, JE VisvaderFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.